Menu
Recruiting NCT06355739

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

No phase Interventional B Lymphocytic Leukemia B Lymphoblastic Lymphoma

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CAR T cell injection.
Who it may be relevant to
Registry conditions: B Lymphocytic Leukemia, B Lymphoblastic Lymphoma. Basic parameters: 3 years — 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Phase II Clinical Study on the Safety and Efficacy of Autotransfusion Agents Targeting CD19 Chimeric Antigen Receptor T Lymphocytes (BIC-19GG, BIC-2019,BIC-2219)in the Treatment of CD19-positive Children With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Overview

To evaluate the safety and efficacy of BIC-19GG, BIC-2019, BIC-2219 in the treatment of relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoma in children

Interventions

  • Device CAR T cell injection
    intravenous injection

Primary outcome measures

  • Overall survival and event-free survival [Time frame: 24 months post CAR-T cell infusion]
Secondary outcome measures (2)
  • Overall remission rate [Time frame: One month post CAR-T cell infusion]
  • Adverse events [Time frame: 12 months post CAR-T cell infusion]

Eligibility criteria

Inclusion criteria

1, age 3-18 years old (including boundary value), male and female;

2\. The patient was clinically diagnosed as relapsed/refractory B acute lymphoblastic leukemia/lymphoblastic lymphoblastic

Patients with tumors who meet one of the following conditions:

  • Complete marrow response (MRD>1%) or not achieved after at least 2 courses of standardized induction regimen chemotherapy

Complete response at the molecular level and immunology (characterized by specific molecular markers and immunophenotypes prior to treatment)

Patients, did not turn negative after treatment);

  • Recurrence during chemotherapy, early recurrence after drug withdrawal (<12 months) or late recurrence after complete remission (≥

12 months) and did not achieve complete remission after 1 course of standard induction regimen (MRD>1%);

  • Recurrence after bone marrow transplantation;
  • Simple bone marrow, simple extramedullary (testicular leukemia, central nervous system leukemia) or combined

recrudescence

3\. Lansky score ≥60;

4, the treatment related antigen test result is positive (CD19/CD20/CD22);

5\. The expected survival period from the signing date of the informed consent is more than 3 months;

6, HGB≥70g/L (blood transfusion);

7, liver and kidney function, cardiopulmonary function meet the following requirements:

  • Creatinine ≤1.5×ULN;
  • Left ventricular ejection fraction ≥50%;
  • Blood oxygen saturation >90%;
  • Total bilirubin ≤1.5×ULN; ALT and AST≤2.5 x ULN.-

Exclusion criteria

  • 1, severe cardiac insufficiency, left ventricular ejection fraction <50%;

2, have a history of severe lung function impairment;

3\. Combined with other advanced malignant tumors;

4, combined with serious infection and can not be effectively controlled;

5, combined with serious autoimmune disease or congenital immune deficiency;

6, active hepatitis (hepatitis B virus deoxyribonucleic acid \[HBVDNA\] or hepatitis C virus ribonucleic acid \[HCVRNA\] positive);

7, human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection;

8\. Have a history of severe allergy to biological products (including antibiotics);

9\. Patients with allogeneic hematopoietic stem cell transplantation still had acute graft-versus-host response (GvHD) one month after immunosuppressant discontinuation;

10, the presence of other serious physical or mental illnesses or abnormalities in laboratory tests that may increase the risk of participating in the study or interfere with the study results, as well as patients deemed unsuitable for participation in the study by the investigator.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

China · 2 centers
  • Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Acad — Tianjin
  • InstituteHBDH — Tianjin

Identifiers

NCT: NCT06355739 · BIC-19GG, BIC-2019,BIC-2219

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗